← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Hemoshear Therapeutics, Llc
Charlottesville, VA
$18,598,772
Total funding
14
Grants
Funding over time
peak $6.2M · FY2010–18$10M$7.5M$5M$2.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$18,598,772 · 14
By mechanism
R44$15,452,624 · 8
N44$1,985,884 · 1
R43$861,757 · 4
N43$298,507 · 1
Investigators at Hemoshear Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Creating a predictive vascular system for early development$2,963,069
R44 · FY2011 · HL
IGF::OT::IGF SBIR PHASE II TOPIC 314, TITLE: VALIDATION OF THE HEMOSHEAR TUMOR MICROENVIRONMENT SYSTEM FOR DRUG DISCOVERY AND DEVELOPMENT$1,985,884
N44 · FY2015 · CA
Development of a human hepatocyte predictive pharmacology and toxicology system.$1,584,146
R44 · FY2013 · DK
Creating a predictive vascular system for early development$1,330,814
R44 · FY2013 · HL
Development of a human physiological multi-cellular liver platform for drug-induced liver injury and disease.$1,261,020
R44 · FY2015 · DK
Validation of targets for therapeutic intervention in NASH$1,211,258
R44 · FY2017 · DK
Validation of a human in vitro system of hepatic steatohepatitis$1,210,475
R44 · FY2016 · DK
Development of an iPSC-derived human hepatocyte platform for drug development.$1,126,573
R44 · FY2015 · GM
Development of a DIVI platform for issue resolution in pre-clinical drug development.$1,126,395
R44 · FY2015 · GM
Identification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism$781,186
R44 · FY2017 · TR
Validation of targets for therapeutic intervention in NASH$650,969
R44 · FY2018 · DK
Development of an iPSC-derived human hepatocyte platform for drug development.$563,284
R44 · FY2016 · GM
Development of a human physiological multi-cellular liver platform for drug-induced liver injury and disease.$463,475
R44 · FY2015 · DK
Identification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism$433,819
R44 · FY2016 · TR
Identification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism$390,596
R44 · FY2018 · TR
IGF::OT::IGF SUPPORT- ADMINISTRATIVE: OTHER$298,507
N43 · FY2013 · CA
Development of an iPSC-derived human hepatocyte platform for drug development.$281,942
R44 · FY2014 · GM
Development of an in vitro system of human hepatic steatosis.$255,128
R43 · FY2015 · DK
Development of an iPSC-derived human vascular system for drug discovery and devel$249,013
R43 · FY2014 · TR
Hemodynamic Co-Culture Liver Model for Drug Discovery and Assessment$190,786
R43 · FY2011 · DK